The rise of immunodeficiency across multiple regions, coupled with new product launches and advancements in existing technologies, are driving growth in the global blood plasma products market. The global market for blood plasma products was valued at USD 25.7 billion in 2018 and is expected to reach USD 35.5 billion by 2023 growing at a CAGR of 6.6 percent, projects BCC Research. Increasing demand in major countries such as the U.S and China are mainly driving market growth. In terms of product types, immunoglobulins capture the major share of the market, and this share is expected to persist due to its adoption level and demand across the globe.
In 2017, North America captured the highest market share of the global immunoglobulins market, at 42 percent of the total, and generated a market value of over USD 4.8 billion. In developed regions, the growing number of chronic disease cases has contributed to the demand for blood plasma. Hospitals, clinics and blood donation centers tend to focus on blood plasma collection by encouraging people to donate plasma, but stringent eligibility rules designed to prevent disease transmission hamper supply. The increasing employment of recombinant plasma products in therapeutic treatments, the high cost of blood plasma therapies, stringent government regulation and low reimbursement policies are current restraints to the global market for blood plasma products.